DNA topoisomerase inhibitor, etoposide, enhances GC-box-dependent promoter activity via Sp1 phosphorylation

Ichiro Niina, Takeshi Uchiumi, Hiroto Izumi, Takayuki Torigoe, Tetsuro Wakasugi, Tomonori Igarashi, Naoya Miyamoto, Takamitsu Onitsuka, Masaki Shiota, Ryuichi Okayasu, Kazuo Chijiiwa, Kimitoshi Kohno

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Modification of transcription factors by anticancer agents plays an important role in both apoptotic and survival signaling. Here we report that both DNA topoisomerase I and II inhibitors such as SN-38 and etoposide, but not cisplatin, 5-fluorouracil or actinomycin D, can induce phosphorylation of the transcription factor Sp1. Furthermore, DNA topoisomerase inhibitors were shown to transactivate GC-box-dependent promoters such as the SV40 and vascular endothelial growth factor promoters. The phosphorylated form of Sp1 was detectable within 30 min of etoposide treatment and was greatly diminished by the presence of the PI3K inhibitor wortmannin and by DNA-dependent protein kinase (DNA-PK) knockdown. We also confirmed that the phosphorylated form of DNA-PK was increased by treatment with both etoposide and SN-38. Taken together, these findings demonstrate a novel genomic response to anticancer agents that induce Sp1 phosphorylation, and might contribute to tumor progression and drug resistance.

Original languageEnglish
Pages (from-to)858-863
Number of pages6
JournalCancer Science
Volume98
Issue number6
DOIs
Publication statusPublished - Jun 1 2007
Externally publishedYes

Fingerprint

irinotecan
Topoisomerase Inhibitors
Etoposide
DNA-Activated Protein Kinase
Phosphorylation
Antineoplastic Agents
Sp1 Transcription Factor
Topoisomerase I Inhibitors
Topoisomerase II Inhibitors
Dactinomycin
Phosphatidylinositol 3-Kinases
Drug Resistance
Fluorouracil
Vascular Endothelial Growth Factor A
Cisplatin
Transcription Factors
Neoplasms

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

DNA topoisomerase inhibitor, etoposide, enhances GC-box-dependent promoter activity via Sp1 phosphorylation. / Niina, Ichiro; Uchiumi, Takeshi; Izumi, Hiroto; Torigoe, Takayuki; Wakasugi, Tetsuro; Igarashi, Tomonori; Miyamoto, Naoya; Onitsuka, Takamitsu; Shiota, Masaki; Okayasu, Ryuichi; Chijiiwa, Kazuo; Kohno, Kimitoshi.

In: Cancer Science, Vol. 98, No. 6, 01.06.2007, p. 858-863.

Research output: Contribution to journalArticle

Niina, I, Uchiumi, T, Izumi, H, Torigoe, T, Wakasugi, T, Igarashi, T, Miyamoto, N, Onitsuka, T, Shiota, M, Okayasu, R, Chijiiwa, K & Kohno, K 2007, 'DNA topoisomerase inhibitor, etoposide, enhances GC-box-dependent promoter activity via Sp1 phosphorylation', Cancer Science, vol. 98, no. 6, pp. 858-863. https://doi.org/10.1111/j.1349-7006.2007.00476.x
Niina, Ichiro ; Uchiumi, Takeshi ; Izumi, Hiroto ; Torigoe, Takayuki ; Wakasugi, Tetsuro ; Igarashi, Tomonori ; Miyamoto, Naoya ; Onitsuka, Takamitsu ; Shiota, Masaki ; Okayasu, Ryuichi ; Chijiiwa, Kazuo ; Kohno, Kimitoshi. / DNA topoisomerase inhibitor, etoposide, enhances GC-box-dependent promoter activity via Sp1 phosphorylation. In: Cancer Science. 2007 ; Vol. 98, No. 6. pp. 858-863.
@article{2d8881c3cf434a099616238dfefb107a,
title = "DNA topoisomerase inhibitor, etoposide, enhances GC-box-dependent promoter activity via Sp1 phosphorylation",
abstract = "Modification of transcription factors by anticancer agents plays an important role in both apoptotic and survival signaling. Here we report that both DNA topoisomerase I and II inhibitors such as SN-38 and etoposide, but not cisplatin, 5-fluorouracil or actinomycin D, can induce phosphorylation of the transcription factor Sp1. Furthermore, DNA topoisomerase inhibitors were shown to transactivate GC-box-dependent promoters such as the SV40 and vascular endothelial growth factor promoters. The phosphorylated form of Sp1 was detectable within 30 min of etoposide treatment and was greatly diminished by the presence of the PI3K inhibitor wortmannin and by DNA-dependent protein kinase (DNA-PK) knockdown. We also confirmed that the phosphorylated form of DNA-PK was increased by treatment with both etoposide and SN-38. Taken together, these findings demonstrate a novel genomic response to anticancer agents that induce Sp1 phosphorylation, and might contribute to tumor progression and drug resistance.",
author = "Ichiro Niina and Takeshi Uchiumi and Hiroto Izumi and Takayuki Torigoe and Tetsuro Wakasugi and Tomonori Igarashi and Naoya Miyamoto and Takamitsu Onitsuka and Masaki Shiota and Ryuichi Okayasu and Kazuo Chijiiwa and Kimitoshi Kohno",
year = "2007",
month = "6",
day = "1",
doi = "10.1111/j.1349-7006.2007.00476.x",
language = "English",
volume = "98",
pages = "858--863",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - DNA topoisomerase inhibitor, etoposide, enhances GC-box-dependent promoter activity via Sp1 phosphorylation

AU - Niina, Ichiro

AU - Uchiumi, Takeshi

AU - Izumi, Hiroto

AU - Torigoe, Takayuki

AU - Wakasugi, Tetsuro

AU - Igarashi, Tomonori

AU - Miyamoto, Naoya

AU - Onitsuka, Takamitsu

AU - Shiota, Masaki

AU - Okayasu, Ryuichi

AU - Chijiiwa, Kazuo

AU - Kohno, Kimitoshi

PY - 2007/6/1

Y1 - 2007/6/1

N2 - Modification of transcription factors by anticancer agents plays an important role in both apoptotic and survival signaling. Here we report that both DNA topoisomerase I and II inhibitors such as SN-38 and etoposide, but not cisplatin, 5-fluorouracil or actinomycin D, can induce phosphorylation of the transcription factor Sp1. Furthermore, DNA topoisomerase inhibitors were shown to transactivate GC-box-dependent promoters such as the SV40 and vascular endothelial growth factor promoters. The phosphorylated form of Sp1 was detectable within 30 min of etoposide treatment and was greatly diminished by the presence of the PI3K inhibitor wortmannin and by DNA-dependent protein kinase (DNA-PK) knockdown. We also confirmed that the phosphorylated form of DNA-PK was increased by treatment with both etoposide and SN-38. Taken together, these findings demonstrate a novel genomic response to anticancer agents that induce Sp1 phosphorylation, and might contribute to tumor progression and drug resistance.

AB - Modification of transcription factors by anticancer agents plays an important role in both apoptotic and survival signaling. Here we report that both DNA topoisomerase I and II inhibitors such as SN-38 and etoposide, but not cisplatin, 5-fluorouracil or actinomycin D, can induce phosphorylation of the transcription factor Sp1. Furthermore, DNA topoisomerase inhibitors were shown to transactivate GC-box-dependent promoters such as the SV40 and vascular endothelial growth factor promoters. The phosphorylated form of Sp1 was detectable within 30 min of etoposide treatment and was greatly diminished by the presence of the PI3K inhibitor wortmannin and by DNA-dependent protein kinase (DNA-PK) knockdown. We also confirmed that the phosphorylated form of DNA-PK was increased by treatment with both etoposide and SN-38. Taken together, these findings demonstrate a novel genomic response to anticancer agents that induce Sp1 phosphorylation, and might contribute to tumor progression and drug resistance.

UR - http://www.scopus.com/inward/record.url?scp=34247843008&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247843008&partnerID=8YFLogxK

U2 - 10.1111/j.1349-7006.2007.00476.x

DO - 10.1111/j.1349-7006.2007.00476.x

M3 - Article

C2 - 17441964

AN - SCOPUS:34247843008

VL - 98

SP - 858

EP - 863

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 6

ER -